Search
AEM-28
go.drugbank.com/drugs/DB17642InvestigationalAEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]
RP-A501
go.drugbank.com/drugs/DB17647InvestigationalRP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane
Reloxiliase
go.drugbank.com/drugs/DB17653ExperimentalReloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]
RP-L301
go.drugbank.com/drugs/DB17661InvestigationalRP-L301 is a lentiviral vector containing the human liver and erythroid pyruvate kinase gene.
rAAV9-rsATP7A
go.drugbank.com/drugs/DB17664ExperimentalA recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
LB-001
go.drugbank.com/drugs/DB17685ExperimentalLB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
ASP-8731
go.drugbank.com/drugs/DB17696InvestigationalASP-8731 is a novel BACH1 inhibitor that potentially induces fetal hemoglobin (HbF). Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]
BBM-H901
go.drugbank.com/drugs/DB17704InvestigationalBBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.[A259048]
Dalcinonacog alfa
go.drugbank.com/drugs/DB17707InvestigationalDalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.[A259058]
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalSIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.